|
Gene: C14orf119 |
Gene summary for C14ORF119 |
Gene summary. |
Gene information | Species | Human | Gene symbol | C14orf119 | Gene ID | 55017 |
Gene name | chromosome 14 open reading frame 119 | |
Gene Alias | C14orf119 | |
Cytomap | 14q11.2 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9NWQ9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55017 | C14orf119 | P44T-E | Human | Esophagus | ESCC | 6.83e-20 | 4.71e-01 | 0.1096 |
55017 | C14orf119 | P47T-E | Human | Esophagus | ESCC | 9.69e-29 | 6.78e-01 | 0.1067 |
55017 | C14orf119 | P48T-E | Human | Esophagus | ESCC | 5.86e-33 | 5.25e-01 | 0.0959 |
55017 | C14orf119 | P49T-E | Human | Esophagus | ESCC | 1.71e-25 | 1.98e+00 | 0.1768 |
55017 | C14orf119 | P52T-E | Human | Esophagus | ESCC | 2.16e-35 | 1.01e+00 | 0.1555 |
55017 | C14orf119 | P54T-E | Human | Esophagus | ESCC | 5.95e-17 | 4.81e-01 | 0.0975 |
55017 | C14orf119 | P56T-E | Human | Esophagus | ESCC | 3.90e-08 | 1.23e+00 | 0.1613 |
55017 | C14orf119 | P57T-E | Human | Esophagus | ESCC | 1.64e-21 | 5.75e-01 | 0.0926 |
55017 | C14orf119 | P61T-E | Human | Esophagus | ESCC | 1.18e-28 | 8.98e-01 | 0.099 |
55017 | C14orf119 | P62T-E | Human | Esophagus | ESCC | 5.10e-68 | 1.26e+00 | 0.1302 |
55017 | C14orf119 | P65T-E | Human | Esophagus | ESCC | 2.58e-39 | 9.05e-01 | 0.0978 |
55017 | C14orf119 | P74T-E | Human | Esophagus | ESCC | 3.90e-48 | 1.55e+00 | 0.1479 |
55017 | C14orf119 | P75T-E | Human | Esophagus | ESCC | 9.75e-81 | 1.61e+00 | 0.1125 |
55017 | C14orf119 | P76T-E | Human | Esophagus | ESCC | 3.62e-40 | 1.34e+00 | 0.1207 |
55017 | C14orf119 | P79T-E | Human | Esophagus | ESCC | 4.38e-53 | 9.87e-01 | 0.1154 |
55017 | C14orf119 | P80T-E | Human | Esophagus | ESCC | 6.62e-57 | 1.61e+00 | 0.155 |
55017 | C14orf119 | P82T-E | Human | Esophagus | ESCC | 2.19e-13 | 8.46e-01 | 0.1072 |
55017 | C14orf119 | P83T-E | Human | Esophagus | ESCC | 5.39e-57 | 1.86e+00 | 0.1738 |
55017 | C14orf119 | P84T-E | Human | Esophagus | ESCC | 6.76e-15 | 9.59e-01 | 0.0933 |
55017 | C14orf119 | P89T-E | Human | Esophagus | ESCC | 4.99e-19 | 1.54e+00 | 0.1752 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C14orf119 | SNV | Missense_Mutation | c.44N>A | p.Ser15Tyr | p.S15Y | Q9NWQ9 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.452) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
C14orf119 | SNV | Missense_Mutation | novel | c.114N>C | p.Glu38Asp | p.E38D | Q9NWQ9 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-D8-A4Z1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
C14orf119 | SNV | Missense_Mutation | novel | c.277G>A | p.Glu93Lys | p.E93K | Q9NWQ9 | protein_coding | tolerated(0.11) | possibly_damaging(0.572) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
C14orf119 | SNV | Missense_Mutation | novel | c.184G>A | p.Val62Ile | p.V62I | Q9NWQ9 | protein_coding | tolerated(0.14) | benign(0.146) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C14orf119 | SNV | Missense_Mutation | c.313N>T | p.Gly105Cys | p.G105C | Q9NWQ9 | protein_coding | deleterious(0.02) | probably_damaging(0.939) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
C14orf119 | SNV | Missense_Mutation | rs751433100 | c.161G>A | p.Arg54His | p.R54H | Q9NWQ9 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
C14orf119 | SNV | Missense_Mutation | novel | c.26N>C | p.Met9Thr | p.M9T | Q9NWQ9 | protein_coding | tolerated_low_confidence(0.18) | benign(0) | TCGA-B5-A11Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C14orf119 | SNV | Missense_Mutation | novel | c.251N>A | p.Gly84Glu | p.G84E | Q9NWQ9 | protein_coding | tolerated_low_confidence(0.08) | benign(0.013) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
C14orf119 | SNV | Missense_Mutation | rs751433100 | c.161N>A | p.Arg54His | p.R54H | Q9NWQ9 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
C14orf119 | SNV | Missense_Mutation | novel | c.322G>A | p.Glu108Lys | p.E108K | Q9NWQ9 | protein_coding | deleterious(0.01) | possibly_damaging(0.857) | TCGA-56-7221-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |